Bausch Health (BHC) Q2 FY26 earnings call

Bausch Health delivered an exceptional second quarter, extending its streak of top-line and bottom-line growth to 13 consecutive quarters. Strong performance across Salix, International, and Solta segments, particularly driven by the successful integration of Solta's China distributor, led to significant revenue and adjusted EBITDA expansion. The company raised its full-year guidance across all key financial metrics, reflecting confidence in its strategic execution and operational excellence, despite anticipating some headwinds in the second half of the year.